Terminated PHASE2 INTERVENTIONAL 1-arm NCT05776875

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Sponsor: Genentech, Inc.

Conditions BCLC Stage B Hepatocellular Carcinoma Hepatocellular Carcinoma

Interventions Atezolizumab Injection Bevacizumab Transarterial chemoembolization

Updated 9 times since 2023 Last updated: Dec 19, 2024 Started: Jun 7, 2023 Primary completion: Dec 5, 2024 Completion: Dec 5, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low enrollment

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

This PHASE2 trial investigates BCLC Stage B Hepatocellular Carcinoma and Hepatocellular Carcinoma and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 9 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Feb 2025 — Present [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Jan 2025 — Feb 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE2
Oct 2023 — Feb 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
May 2023 — Oct 2023 [monthly]

Not Yet Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States